Prophylaxis News and Research RSS Feed - Prophylaxis News and Research

Crealta publishes review of post-hoc safety analysis completed for Krystexxa

Crealta publishes review of post-hoc safety analysis completed for Krystexxa

Crealta Pharmaceuticals LLC, today announced that the Journal of Clinical Rheumatology published a comprehensive review of a post-hoc safety analysis that was completed for Krystexxa (pegloticase), including data from the two pivotal randomized Phase III trials and one open-label extension trial. [More]
NTU scientists discover how malaria parasite develops resistance towards front-line drugs

NTU scientists discover how malaria parasite develops resistance towards front-line drugs

Scientists from Nanyang Technological University have discovered exactly how the malaria parasite is developing resistance towards the most important front-line drugs used to treat the disease. [More]
Simple rectal swab cultures can thwart drug-resistant E. coli in patients undergoing TRUSBx procedures

Simple rectal swab cultures can thwart drug-resistant E. coli in patients undergoing TRUSBx procedures

Some infections after prostate biopsy due to drug-resistant Escherichia coli can be thwarted by simple rectal swab cultures prior to the procedure. The cultures test for antibiotic-resistant E. coli, and the findings are used to direct the selection of antimicrobial prophylaxis used for the procedure, according to Rhode Island Hospital researchers. [More]
Novo Nordisk reports positive data from Novoeight phase 3 study in people with haemophilia A

Novo Nordisk reports positive data from Novoeight phase 3 study in people with haemophilia A

Today, Novo Nordisk announced a new analysis of phase 3 data demonstrating people with haemophilia A who had the highest annualised bleeding rate (ABR) during initial treatment with Novoeight (Antihemophilic Factor [Recombinant]) showed the largest reduction in bleeding over the duration of treatment. [More]
UCLA researchers devise plan to reduce HIV transmission in Africa

UCLA researchers devise plan to reduce HIV transmission in Africa

While Ebola has attracted much of the world's attention recently, a severe HIV epidemic rages on around the world and in sub-Saharan Africa in particular. Globally, more than 34 million people are infected with HIV; in sub-Saharan Africa alone, 3 million new infections occur annually. [More]
Baxter seeks FDA approval of BAX 855 for treatment of people with hemophilia A

Baxter seeks FDA approval of BAX 855 for treatment of people with hemophilia A

Nektar Therapeutics reported that partner Baxter International Inc. today announced that the company has submitted a biologics license application (BLA) to the United States Food and Drug Administration for the approval of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)]. [More]
New smartphone app may help improve prescribing of antibiotics within RCSI Hospitals Group

New smartphone app may help improve prescribing of antibiotics within RCSI Hospitals Group

A new smartphone app has been developed by the RCSI (Royal College of Surgeons in Ireland) Hospitals Group, in association with the Dublin North East Healthcare-Associated Infection (HCAI) Committee, which will provide healthcare professionals in hospitals within the RCSI Hospitals Group with immediate access to guidelines for antimicrobial prescribing. [More]
NPS MedicineWise Reducing Antibiotic Resistance program focuses on urinary tract infections

NPS MedicineWise Reducing Antibiotic Resistance program focuses on urinary tract infections

The next phase of the NPS MedicineWise Reducing Antibiotic Resistance program for health professionals has launched today focused on the complex topic of managing urinary tract infections (UTIs). [More]
University of Sheffield scientists find significant rise in serious heart infection

University of Sheffield scientists find significant rise in serious heart infection

Scientists at the University of Sheffield have identified a significant rise in the number of people diagnosed with a serious heart infection alongside a large fall in the prescribing of antibiotic prophylaxis to dental patients. [More]
Three Johns Hopkins hospitals recognized as Top Performer on Key Quality Measures

Three Johns Hopkins hospitals recognized as Top Performer on Key Quality Measures

Three Johns Hopkins Medicine hospitals are recipients of The Joint Commission’s 2013 Top Performer on Key Quality Measures award. The Top Performer program recognizes hospitals for improving performance on evidence-based interventions that increase the chances of healthy outcomes for patients with certain conditions, including heart attack, heart failure, pneumonia, surgical care, children’s asthma, stroke, venous thromboembolism (VTE) and perinatal care, as well as for inpatient psychiatric services and immunizations. [More]
Dosing of antiretroviral medication to prevent HIV infection differs by sex

Dosing of antiretroviral medication to prevent HIV infection differs by sex

A mathematical model developed by NIH grantees predicts that women must take the antiretroviral medication Truvada daily to prevent HIV infection via vaginal sex, whereas just two doses per week can protect men from HIV infection via anal sex. [More]
Verbal abuse worsens bipolar disease outcome

Verbal abuse worsens bipolar disease outcome

Experiencing verbal abuse in childhood has a lasting negative effect on the course of bipolar disorder, researchers have found. [More]

Group B streptococcus is the leading cause of infection in newborns

The findings suggest that this disturbing trend could be due the emergence of more virulent group B streptococcal strains and call for a renewed evaluation of preventive strategies to reduce neonatal disease. [More]
New specialist outpatient vaccinations clinic for at-risk people to be opened at MedUni Vienna

New specialist outpatient vaccinations clinic for at-risk people to be opened at MedUni Vienna

At the Medical University of Vienna, Austria's first specialist vaccinations clinic for at-risk groups will open on 22nd October 2014 with an "Open Doors Day". This clinic specialises in patients who, as a result of illness or disease, require personalised care in relation to vaccinations. [More]
Eisai, Helsinn Group announce FDA approval of AKYNZEO for prevention of CINV

Eisai, Helsinn Group announce FDA approval of AKYNZEO for prevention of CINV

Helsinn Group and Eisai Inc. announced today that the Food and Drug Administration (FDA) approved AKYNZEO® for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. [More]
Survey finds prevalence of antimicrobial-drug use in U.S. hospitals

Survey finds prevalence of antimicrobial-drug use in U.S. hospitals

A one-day prevalence survey of 183 hospitals found that approximately 50 percent of hospitalized patients included in the survey were receiving antimicrobial drugs, and that about half of these patients were receiving 2 or more antimicrobial drugs, according to a study in the October 8 JAMA, a theme issue on infectious disease. Most antimicrobial use was for infection treatment. [More]
Acacia Pharma reports positive results from APD421 Phase 3 studies for management of PONV

Acacia Pharma reports positive results from APD421 Phase 3 studies for management of PONV

Acacia Pharma announces positive Phase 3 results with APD421 for the management of post-operative nausea & vomiting (PONV). The data generated demonstrated a statistically significant reduction in the incidence of PONV with APD421 compared to placebo in adult surgical patients at moderate to high risk of suffering PONV (PONV is defined as any episode of emesis or use of antiemetic rescue medication in the first 24 hours after surgery). [More]
AfriCoLeish launches Phase III clinical study to test 2 treatments for HIV-VL co-infected patients

AfriCoLeish launches Phase III clinical study to test 2 treatments for HIV-VL co-infected patients

The international research & development (R&D) consortium, AfriCoLeish, formed by six research organizations from East Africa and Europe, has launched a Phase III clinical study to address the extreme difficulty in treating visceral leishmaniasis (VL) in patients who also are HIV-positive. [More]
UCSF gets CDC grant to provide expert guidance to clinicians who prescribe anti-HIV medications

UCSF gets CDC grant to provide expert guidance to clinicians who prescribe anti-HIV medications

The UCSF Clinician Consultation Center at San Francisco General Hospital and Trauma Center has been funded by the Centers for Disease Control and Prevention to provide a PrEPline, a telephone consultation service that gives expert guidance to healthcare providers across the nation who prescribe antiretroviral medications to HIV uninfected individuals to prevent HIV. [More]
NCCN ORP awards four research grants to advance development of nintedanib

NCCN ORP awards four research grants to advance development of nintedanib

The National Comprehensive Cancer Network Oncology Research Program has awarded four grants to investigators to evaluate and define the clinical effectiveness of the investigational compound nintedanib (BIBF 1120) in non-small cell lung, colorectal, and gastrointestinal cancers. [More]